Peer review reports
From: Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
Original Submission |
24 Jun 2022 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
Resubmission - Version 4 |
|
Submitted |
Manuscript version 4
|
23 Jul 2022 |
Reviewed |
Reviewer Report
|
7 Aug 2022 |
Reviewed |
Reviewer Report - Hung-yu Huang
|
28 Aug 2022 |
Author responded |
Author comments - Yongchang Zhang
|
Resubmission - Version 5 |
28 Aug 2022 |
Submitted |
Manuscript version 5
|
Publishing |
31 Aug 2022 |
Editorially accepted |
|
5 Sep 2022 |
Article published |
10.1186/s12885-022-10045-0
|
Learn about peer review